Interestingly, the use of tocilizumab, an anti-IL-6 therapy, has been shown to be associated with a rapid QTc shortening in patients with rheumatoid arthritis, which was correlated with the decrease in both CRP and tumor necrosis factor (TNF)-α levels [21]. This evidence concerns the gene CRP and rheumatoid arthritis.